Real-life multicenter experience of long-term treatment with venetoclax plus azacitidine for acute myeloid leukemia in China

Abstract The combination of venetoclax (VEN) and azacitidine (AZA) has transformed the treatment of acute myeloid leukemia (AML) in patients ineligible for intensive therapy. Nevertheless, real-world evidence on long-term outcomes in patients with AML treated with VEN + AZA remains limited. A retros...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Xuexing Chen, Qiong Yan, Chunfang Li, Fei Liu, Shaojun Guo, Juan Zhao, Yan Liang, Haiyan Wang, Weiming Li, Guolin Yuan
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Nature Portfolio 2026-04-01
Цуврал:	Scientific Reports
Нөхцлүүд:	Venetoclax Acute myeloid leukemia Long-term treatment Efficacy Prognostic factors
Онлайн хандалт:	https://doi.org/10.1038/s41598-026-50426-0
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!